49448822 Pharmaceutical Industries Ppt
-
Upload
choudhary-ashu -
Category
Documents
-
view
233 -
download
0
Transcript of 49448822 Pharmaceutical Industries Ppt
8/4/2019 49448822 Pharmaceutical Industries Ppt
http://slidepdf.com/reader/full/49448822-pharmaceutical-industries-ppt 1/13
Pharmaceutical
Industry
Submitted by- ankit mishra
8/4/2019 49448822 Pharmaceutical Industries Ppt
http://slidepdf.com/reader/full/49448822-pharmaceutical-industries-ppt 2/13
1. Introduction
2. About indian pharma industries
3. Growth of pharma industries
4. Key players
5. Market share
6. Key products
7. Impact on G.D.P.
8. S.W.O.T.analysis
9. Conclusion
8/4/2019 49448822 Pharmaceutical Industries Ppt
http://slidepdf.com/reader/full/49448822-pharmaceutical-industries-ppt 3/13
INTRODUCTION
Pharmaceutical Industry in India is one of the largest
and most advanced among the developing countries
The Indian pharmaceutical industry has come a long
way from waiting for imports of bulk drugs from
global players to breaking new grounds in medical
research worldwide.
8/4/2019 49448822 Pharmaceutical Industries Ppt
http://slidepdf.com/reader/full/49448822-pharmaceutical-industries-ppt 4/13
I NDIAN PHARMACEUTICAL I NDUSTRY
IPI is ranked 4th in volume terms and 11th in value
terms globally.
Around 70% of the country's demand for bulk drugs,
drug intermediates, pharmaceutical formulations,chemicals, tablets, capsules, orals and vaccines is met by
IPI.
The Pharmaceutical industry in India is fragmented
with over 3,000 small/medium sized generic
pharmaceutical manufacturers.
8/4/2019 49448822 Pharmaceutical Industries Ppt
http://slidepdf.com/reader/full/49448822-pharmaceutical-industries-ppt 5/13
GROWTH OF THE INDUSTRY
Worth of the pharma industry ² $ 6billion
Accounts for - 1% of the world'spharma industry in value terms and8% in volume terms. .
Revenues generated - US$ 7.6 bn
and have grown at an average rate of 10% over last f ive years
8/4/2019 49448822 Pharmaceutical Industries Ppt
http://slidepdf.com/reader/full/49448822-pharmaceutical-industries-ppt 6/13
K EY PRODUCTS
Medicines
Medical equipments
Surgical goods
Operation accessories
I.V.f luids
Injections
8/4/2019 49448822 Pharmaceutical Industries Ppt
http://slidepdf.com/reader/full/49448822-pharmaceutical-industries-ppt 7/13
Ranbaxy*
Dr. Reddy's
Cipla
Lupin
Nicholas PiramalSun
Pharmaceuticals
GSK
Cadila
Healthcare
Aurobindo
Wockhardt*
Key players in pharmaceutical industries
8/4/2019 49448822 Pharmaceutical Industries Ppt
http://slidepdf.com/reader/full/49448822-pharmaceutical-industries-ppt 8/13
MARKET SHARE
55%33%
9%
3%
Sales
1st Qtr 2nd Qtr 3rd Qtr 4th Qtr
IndianTraditionalMedicineMarketSize, 2009
(USD m)
Ayurveda-55%
Homeopathy-33%
Unani-9%
Biochemic-3%
Indian TraditionalMedicine System(ISM) -2009
� ISM market for
products in India in2006 ² USD 400m, grew at 8%
� Over 82% of it - Ayurveda,
8/4/2019 49448822 Pharmaceutical Industries Ppt
http://slidepdf.com/reader/full/49448822-pharmaceutical-industries-ppt 9/13
R OLE OF PHARMACEUTICAL I NDUSTRY IN
I NDIA S GDP
It ranks 4th in the world, pertaining to the volume of sales
The estimated worth of the Indian Pharmaceutical Industry is US$ 6 billion
The growth rate of the industry is 13% per year
The current revenues are estimated at US$5.5 billion
and it is expected to grow at a compounded annual growth rate of 19% and touch US$25 billion in
revenue by 2015.
8/4/2019 49448822 Pharmaceutical Industries Ppt
http://slidepdf.com/reader/full/49448822-pharmaceutical-industries-ppt 10/13
Strengths :-
1.Cost Competitiveness
2 Developed Industry with Strong
Manufacturing Base3.Well Established R&D infrastructure
4. Access to pool of highly trained
scientists,
Opportunities :-
1. Significant export potential.
2. Marketing alliances for MNC products in
domestic market and international market.3.Contract manufacturing arrangements with
MNCs
Weaknesses:-
1. Low investments in innovative
R&D.
2. Lack of resources to compete with
MNCs for New Drug Discovery &
Research3. Lack of strong linkages between
industry and academia.
Threats :-
1.Product patent regime poses serious
challenge to domestic industry unless it invests
in research and development
2. R&D efforts of Indian pharmaceutical
companies hampered by lack of enablingregulatory requirement
3. Export effort hampered by procedural
hurdles in India as well as non-tariff barriers
imposed abroad.
8/4/2019 49448822 Pharmaceutical Industries Ppt
http://slidepdf.com/reader/full/49448822-pharmaceutical-industries-ppt 11/13
F UTURE OF I NDIAN PHARMA INDUSTRY
The key to survival would be the exponential growth of
R&D expenditure. Indian companies need product
patent protection to encourage research in developing
inexpensive drugs that suit the Indian disease profile.The obligations imposed on India are going to have a
significant impact on India·s successful bulk and
formulation-oriented pharmaceutical industry. Indian
companies could focus on producing patented drugs under license from foreign companies or generating
revenues from producing generic drugs.
8/4/2019 49448822 Pharmaceutical Industries Ppt
http://slidepdf.com/reader/full/49448822-pharmaceutical-industries-ppt 12/13
CONCLUSION
Pharma industry being a growth industry
Unaff ected by the business cycle
As per the present growth rate, the IndianPharma Industry is expected to be a US$ 25
billion industry by the year 2015 India has
competitive strength in research services
availability of low cost skilled doctors andscientists
large patient population with diverse diseasecharacteristics
adherence to international quality standards
VLSS agencies recommends investment in thisindustry to be a wise decision.